EMA Application withdrawn: Kiacta (eprodisate disodium) — Neurochem Luxco II SARL

View source ↗

Summary

EMA withdrew the application for Kiacta (eprodisate disodium) in the treatment area of amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• KIACTA

Snippet

Status: Application withdrawn. Therapeutic area: Amyloidosis. MAH: Neurochem Luxco II SARL. Decision date: 31/12/2009. Orphan medicine